scholarly article | Q13442814 |
P356 | DOI | 10.1038/NCPONC1215 |
P698 | PubMed publication ID | 18762793 |
P50 | author | Linda T Vahdat | Q40149511 |
P2860 | cites work | Postoperative dose-dense sequential chemotherapy with epirubicin, paclitaxel and CMF in patients with high-risk breast cancer: safety analysis of the Hellenic Cooperative Oncology Group randomized phase III trial HE 10/00. | Q33377581 |
Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer | Q34601123 | ||
Randomised trial: survival benefit and safety of adjuvant dose-dense chemotherapy for node-positive breast cancer | Q36614607 | ||
Weekly paclitaxel in the adjuvant treatment of breast cancer. | Q37346811 | ||
Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials | Q46828225 | ||
HER2 and Response to Paclitaxel in Node-Positive Breast Cancer | Q57578418 | ||
Randomized Trial of Dose-Dense Versus Conventionally Scheduled and Sequential Versus Concurrent Combination Chemotherapy as Postoperative Adjuvant Treatment of Node-Positive Primary Breast Cancer: First Report of Intergroup Trial C9741/Cancer and Leu | Q57578575 | ||
P433 | issue | 10 | |
P304 | page(s) | 570-571 | |
P577 | publication date | 2008-09-02 | |
P1433 | published in | Nature Clinical Practice Oncology | Q15752073 |
P1476 | title | Choosing a taxane for adjuvant treatment of breast cancer: more than a flip of the coin? | |
P478 | volume | 5 |
Q34274152 | GRP78 as potential predictor for breast cancer response to adjuvant taxane therapy |
Q36825817 | Pathological complete response rate in hormone receptor-negative breast cancer treated with neoadjuvant FEC, followed by weekly paclitaxel administration: A retrospective study and review of the literature |
Search more.